Skip to main content
Image coming soon

GEN4926 Mastering Ophthalmic Drug Development Strategy

$199.00
Adding to cart… The item has been added

The Executive Diagnostic and Governance Toolkit

Mastering Ophthalmic Drug Development Strategy

Score your own function red, amber or green, find out which part is weakest, and walk into the next budget round able to defend what you want to fix. Built for leaders reviewing decide whether to prioritize oral bioavailability or retinal targeting in phase progression.

$199 one-time
30-day money-back guarantee Verified against latest insights, updated access provided within 24h

Each order is checked and updated against the latest insights before delivery. That is why access takes up to 24 hours rather than being instant.

What you walk out with
A scored, ranked picture of your own function, and a defensible answer to what to fix first.
1 You stop guessing where you stand.
You finish with a score, not an opinion: every part of your function rated red, amber or green, with the weakest ranked first. Evidence: a Quick Scan for the shape of it, then seven domain assessments of 30 scored questions each, 210 in all, rolled into one scorecard, plus a maturity radar and a current-versus-target gap analysis.
2 You can defend the decision.
You walk into the budget round with the gap named, the owner named and done defined, instead of a case built on instinct. Evidence: project charter, scope statement, RACI, requirements traceability and work breakdown structure, pre-filled in your domain's language.
3 The work actually moves.
The month after the decision is already built, so nothing stalls waiting for someone to design a form. Evidence: more than 60 project templates across all five PMBOK process groups, plus runbooks, SOPs, a KPI framework, audit checklists and a risk matrix. 55 to 65 files in total.
4 You use it the day it lands.
No blank templates to interpret. Every workbook opens with what it is, who uses it, when, how, a 1 to 5 scoring guide, what good looks like, and a worked example you delete and type over.
The Quick Scan is one sitting. You will know your weakest area before the day is out.
Nothing in it is generic project management: the build rejects any file that could belong to another course. Updated after you enrol, so it reflects where the work stands now. The 144-chapter course is included behind it, for the parts you want to go deeper on.
Choosing between retinal targeting and oral bioavailability could make or break your development timeline.

The situation this is built for

You're leading clinical development for an ophthalmic compound where route of administration isn't settled. Your CMC team pushes for oral formulation scalability. Your toxicology team flags systemic exposure risks. Your clinical team wants localized delivery to maximize retinal concentration. No framework exists to weigh these trade-offs objectively. You're expected to decide — but with no standard process, the decision feels like guesswork. Delay compounds program risk. A wrong call wastes millions and delays patient access.

Who this is for

Clinical development lead in ophthalmology, responsible for integrating CMC, PK, toxicology, and clinical strategy into a coherent development path for retinal therapies.

Who this is not for

This is not for preclinical scientists, formulation chemists, or regulatory affairs specialists focused on submission mechanics. It is not for generalists without decision authority in ophthalmic program strategy.

What you walk away with

  • Align cross-functional teams on delivery route decisions
  • Reduce time spent in formulation deadlock
  • Increase confidence in retinal exposure targets
  • Improve predictability of clinical outcomes
  • Defend strategic choices in governance reviews

How this maps to your situation

  • Recognizing the delivery route dilemma in early development
  • Gathering and interpreting cross-functional data
  • Modeling outcomes under different delivery assumptions
  • Making and defending the final strategic decision

Before vs. after

Before
You're navigating conflicting inputs from CMC, toxicology, and clinical teams without a structured way to decide between retinal targeting and systemic delivery.
After
You lead with a validated framework that aligns stakeholders, reduces development risk, and accelerates confident decision-making on delivery strategy.

What's included with your purchase

  • 12 modules with 12 chapters each (144 chapters)
  • Downloadable templates and worked examples for every module
  • Hand-built implementation playbook delivered alongside course access
  • 30-day money-back guarantee

Delivery and format

  • Course and learning environment access provisioned within 24 hours of purchase
  • Hand-built implementation playbook delivered alongside course access

Format: Text-based modules and chapters in the Art of Service learning environment, plus downloadable templates and worked examples for every chapter, plus the hand-built implementation playbook delivered alongside course access.

Time investment: Approximately 8 hours of focused work across 12 modules, designed to be completed alongside active program decisions.

If nothing changes
Delaying the delivery route decision leads to parallel development paths, wasted resources, misaligned teams, and late-stage failures due to poor retinal exposure or unacceptable systemic toxicity. Without a decision framework, governance reviews become circular, and programs lose momentum.

How this compares to the alternatives

Unlike general drug development courses, this program focuses exclusively on ophthalmic delivery trade-offs, providing actionable frameworks, templates, and decision tools specifically for retinal targeting vs. systemic exposure choices. No other resource integrates PK, toxicology, CMC, and clinical strategy in this context.

Also included: the full course, for when you want the reasoning behind a finding (12 modules, 144 chapters)

Depth reference. The diagnostic and the templates stand on their own; this is what to read when you want the reasoning behind a finding.

Module 1. Defining the Core Dilemma in Ophthalmic Development
Establish the central tension between retinal targeting and systemic delivery as the foundation for strategic decision-making.
12 chapters in this module
  1. Understanding the retinal blood barrier and its impact on drug delivery
  2. Mapping systemic exposure risks in chronic ocular therapy programs
  3. Evaluating patient compliance factors in route-of-administration decisions
  4. Assessing the role of plasma protein binding in ocular distribution
  5. Differentiating anterior vs. posterior segment targeting challenges
  6. Reviewing historical failures due to poor route-of-administration choices
  7. Analyzing the impact of first-pass metabolism on oral candidates
  8. Identifying key decision-makers in delivery route governance
  9. Documenting assumptions about retinal residence time
  10. Estimating effective concentration thresholds for retinal targets
  11. Balancing local efficacy with systemic safety margins
  12. Establishing criteria for early route-of-administration commitment
Module 2. Anatomy and Pharmacokinetic Constraints of the Eye
Ground decision-making in the physiological realities of ocular drug distribution.
12 chapters in this module
  1. Tracing drug movement from systemic circulation to retinal tissue
  2. Quantifying vitreous clearance rates in human and animal models
  3. Modeling retinal pigment epithelium permeability in vitro
  4. Interpreting aqueous humor sampling limitations in clinical trials
  5. Estimating choroidal blood flow effects on drug washout
  6. Differentiating trans-scleral vs. trans-corneal absorption pathways
  7. Applying allometric scaling to retinal exposure predictions
  8. Evaluating intraocular pressure effects on drug distribution
  9. Accounting for blood-retinal barrier integrity in disease states
  10. Measuring retinal drug concentrations in preclinical species
  11. Predicting human retinal exposure from animal PK data
  12. Adjusting for retinal binding capacity in dose calculations
Module 3. Comparative Analysis of Delivery Modalities
Systematically evaluate intravitreal, oral, topical, and sustained-release options.
12 chapters in this module
  1. Calculating retinal bioavailability across administration routes
  2. Assessing patient burden in repeated intravitreal injection regimens
  3. Estimating systemic drug exposure from oral formulations
  4. Evaluating corneal penetration limits for topical agents
  5. Reviewing depot formulation longevity and release kinetics
  6. Comparing immunogenicity risks across delivery methods
  7. Analyzing local toxicity profiles by administration route
  8. Mapping manufacturing complexity by modality
  9. Projecting annual treatment frequency by delivery method
  10. Estimating cost-of-goods impact on delivery choice
  11. Assessing cold chain requirements for biologic formulations
  12. Forecasting adherence rates by patient population and route
Module 4. Translational Pharmacokinetic Modeling for Retinal Targets
Build predictive models that inform early route selection.
12 chapters in this module
  1. Constructing compartmental models for retinal drug distribution
  2. Incorporating protein binding adjustments in ocular PK
  3. Validating model assumptions with microdialysis data
  4. Estimating unbound fraction in retinal tissue
  5. Integrating ocular perfusion rates into PK simulations
  6. Adjusting for retinal metabolism in exposure projections
  7. Using IVIVE to predict human retinal concentrations
  8. Calibrating models with preclinical imaging data
  9. Sensitivity testing for blood-retinal barrier permeability
  10. Back-calculating required plasma levels for retinal efficacy
  11. Projecting dosing frequency from elimination half-life
  12. Assessing model robustness under disease progression
Module 5. Toxicology Implications of Systemic Exposure
Evaluate safety risks associated with high plasma concentrations.
12 chapters in this module
  1. Identifying off-target binding sites with systemic distribution
  2. Assessing QT prolongation risk in oral ophthalmic candidates
  3. Reviewing hepatic enzyme induction potential in chronic dosing
  4. Evaluating renal clearance thresholds for metabolite safety
  5. Mapping tissue accumulation in long-term toxicology studies
  6. Interpreting hERG assay results in context of plasma Cmax
  7. Calculating safety margins for systemic exposure
  8. Assessing immunomodulatory effects at therapeutic doses
  9. Reviewing adrenal suppression potential in corticosteroid analogs
  10. Monitoring for drug-drug interactions in polypharmacy populations
  11. Evaluating bone marrow suppression risks in chronic use
  12. Documenting organ-specific toxicity findings for governance
Module 6. Clinical Endpoint Design for Local vs. Systemic Therapies
Align trial design with delivery route to ensure meaningful outcomes.
12 chapters in this module
  1. Selecting OCT parameters as primary efficacy endpoints
  2. Designing visual acuity endpoints for early intervention trials
  3. Aligning endpoint timing with expected retinal residence
  4. Choosing between anatomical and functional outcome measures
  5. Adjusting for disease progression rate in endpoint selection
  6. Incorporating patient-reported outcomes in low-burden regimens
  7. Designing crossover trials for delivery route comparison
  8. Setting non-inferiority margins for systemic alternatives
  9. Validating surrogate markers for retinal drug concentration
  10. Accounting for injection frequency in quality-of-life metrics
  11. Assessing microperimetry sensitivity for focal therapy
  12. Planning endpoint assessments around expected peak concentrations
Module 7. CMC and Formulation Trade-Offs in Ophthalmic Programs
Navigate chemical and manufacturing challenges inherent to delivery decisions.
12 chapters in this module
  1. Evaluating solubility limitations for oral bioavailability
  2. Assessing stability requirements for intravitreal formulations
  3. Designing sustained-release polymers for posterior segment
  4. Optimizing molecular weight for trans-scleral penetration
  5. Balancing lipophilicity and aqueous solubility for ocular delivery
  6. Reviewing crystallization risks in depot formulations
  7. Adjusting pH for ocular tolerability and shelf life
  8. Evaluating preservative-free requirements for chronic use
  9. Assessing excipient safety in repeated ocular exposure
  10. Projecting batch yield differences by formulation type
  11. Mapping analytical method development timelines
  12. Planning for scale-up challenges in sterile manufacturing
Module 8. Regulatory Strategy for Route-of-Administration Decisions
Anticipate agency expectations and align development plans accordingly.
12 chapters in this module
  1. Defining comparability in route-of-administration changes
  2. Preparing justification for systemic delivery of ocular agents
  3. Addressing route-specific safety monitoring requirements
  4. Documenting retinal exposure data for regulatory submissions
  5. Aligning with agency guidance on local vs. systemic effects
  6. Planning for route-specific clinical trial designs
  7. Responding to questions about off-target exposure
  8. Submitting bridging data for delivery modifications
  9. Justifying dose selection based on ocular PK
  10. Preparing for pre-IND discussions on administration route
  11. Addressing pediatric formulation considerations
  12. Demonstrating control of delivery variability in filings
Module 9. Stakeholder Alignment in Cross-Functional Governance
Lead consensus among CMC, toxicology, clinical, and commercial teams.
12 chapters in this module
  1. Facilitating delivery route decision meetings with core team
  2. Presenting comparative risk-benefit assessments to governance
  3. Translating PK data into strategic implications for executives
  4. Aligning commercial forecasting with administration burden
  5. Incorporating payer perspectives on treatment frequency
  6. Managing differing priorities between research and development
  7. Documenting decision rationale for audit and review
  8. Escalating unresolved trade-offs to portfolio committee
  9. Integrating patient advocacy input on delivery preferences
  10. Balancing innovation with development risk tolerance
  11. Setting decision criteria before data becomes available
  12. Communicating route decisions to external partners
Module 10. Patient-Centric Considerations in Delivery Design
Incorporate adherence, burden, and real-world use into strategic choices.
12 chapters in this module
  1. Assessing injection anxiety in patient populations
  2. Evaluating visual acuity requirements for self-administration
  3. Designing delivery systems for aging patient dexterity
  4. Mapping caregiver involvement in treatment regimens
  5. Estimating real-world adherence by administration route
  6. Incorporating telemedicine compatibility in follow-up design
  7. Assessing health literacy barriers to complex regimens
  8. Evaluating transportation access for frequent visits
  9. Designing packaging for low-light vision impairment
  10. Planning for home health support in high-frequency dosing
  11. Assessing patient willingness to accept systemic exposure
  12. Integrating patient-reported burden into benefit-risk analysis
Module 11. Portfolio Positioning and Competitive Benchmarking
Evaluate delivery strategy in the context of market alternatives.
12 chapters in this module
  1. Mapping competitor administration routes in retinal space
  2. Assessing market share trends by delivery frequency
  3. Evaluating payer reimbursement patterns by route
  4. Benchmarking safety profiles across delivery modalities
  5. Analyzing discontinuation rates in real-world studies
  6. Positioning novel delivery mechanisms for differentiation
  7. Assessing lifecycle management potential by formulation
  8. Evaluating combination therapy feasibility by route
  9. Forecasting physician adoption by treatment burden
  10. Analyzing clinical trial enrollment by regimen intensity
  11. Positioning oral options in specialist vs. primary care
  12. Assessing intellectual property landscape for delivery methods
Module 12. Decision Framework Integration and Execution
Apply the complete framework to make and implement a defensible choice.
12 chapters in this module
  1. Assembling evidence from all functions for route decision
  2. Applying weighted scoring model to delivery options
  3. Documenting key assumptions and uncertainties
  4. Presenting decision package to governance committee
  5. Setting go/no-go criteria for delivery path
  6. Planning for adaptive design in early development
  7. Designing phase-appropriate monitoring for safety signals
  8. Integrating formulation flexibility into development plan
  9. Establishing triggers for route re-evaluation
  10. Communicating decision to clinical operations teams
  11. Aligning CMC timelines with strategic choice
  12. Tracking decision impact on program milestones

Frequently asked

Is this course about new delivery technologies?
No. This course is about the decision-making process for choosing between delivery routes, not the technical details of specific technologies.
How is the course structured?
12 modules, each containing 12 chapters (144 chapters total).
Will this help me justify my delivery route choice to senior leadership?
Yes. The course includes frameworks for building evidence-based decision packages suitable for governance and portfolio review.
Can I apply this while my program is ongoing?
Yes. The content is designed to be used in real time, with templates that integrate into active development planning.
Does this cover regulatory expectations for ophthalmic agents?
Yes. Module 8 addresses regulatory strategy, including how to justify route-of-administration choices to agencies.
What formats do the templates come in?
The implementation playbook downloads as PDF and editable XLSX. The course reads in your learning environment and exports to PDF for offline use. The files are yours to keep.
Can I share this with my team?
The licence is per person. Team pricing opens from three seats: reply to the order confirmation with TEAM and we will set it up.
How quickly can I start?
The diagnostic is one sitting and the templates work straight out of the kit. Account access takes up to 24 hours rather than being instant, because every order is checked and updated against the latest sources before it is delivered.
$199 one-time. Approximately 8 hours of focused work across 12 modules, designed to be completed alongside active program decisions..

Within 24 hours your account in the learning environment is provisioned and the tailored implementation playbook is delivered alongside it.

30-day money-back guarantee·Know your weakest area today·210 scored questions·Course included· Account access within 24 hours
30-day money-back guarantee, no questions asked.
Thousands of organisations have bought from The Art of Service since 2000.
!